Balaxi (BALAXI) | Stock Overview & Key Data
Balaxi Performance Comparison
Stock Range
Today's Range
Low: ₹42.56
High: ₹46.19
on August 8, 2025
52 Week Range
Low: ₹42.56
High: ₹127.45
on August 8, 2025
on September 16, 2024
All-Time High: ₹216.04 on October 12, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR2.4B
EPS
4.54
P/E Ratio (TTM)
10.50
Forward P/E
N/A
P/B Ratio
1.14
PEG Ratio
N/A
Div. Yield
N/A
ROE
-1.24%
Beta
0.594
Debt to Equity
9.64
Financial Highlights
Profitability
Gross Margin
48.13%
Operating Margin
21.39%
Profit Margin
-0.99%
Returns and Earnings
Return on Assets (TTM)
11.20%
Return on Equity (TTM)
-1.24%
EBITDA
INR335.0M
Net Income (TTM)
INR-23.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR47.40
Quarterly Revenue Growth (YoY)
-25.80%
Quarterly Earnings Growth (YoY)
35.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Balaxi BALAXI | 2.43B Small-cap | -7.79% | -12.76% | -17.12% | -35.78% | -39.35% | -60.10% | -50.18% | -43.77% |
| Biocon BIOCON | 486.32B Large-cap | -10.79% | -7.47% | 2.14% | -9.39% | -7.33% | 8.09% | 17.05% | -7.82% |
| OneSource Specialty ONESOURCE | 214.64B Large-cap | 1.94% | -5.48% | 18.19% | 22.64% | 10.61% | 10.61% | 10.61% | 10.61% |
| Dishman Carbogen DCAL | 37.57B Small-cap | -3.47% | -8.84% | 27.79% | -2.26% | -17.23% | 22.14% | 106.15% | 27.13% |
| Zota Health Care ZOTA | 31.09B Small-cap | -0.78% | -2.36% | 45.12% | 25.14% | 50.88% | 85.82% | 335.52% | 755.41% |
| Panacea Biotec PANACEABIO | 25.12B Small-cap | 2.01% | 1.32% | -18.83% | 4.32% | -6.84% | 204.85% | 215.33% | 148.03% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
239K
Average 90-Day Volume
390K
Balaxi Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Balaxi would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BALAXI's 52-week high and low?
- In the last 52 weeks, Balaxi reached a high of ₹127.45 (on September 16, 2024) and a low of ₹42.56 (on August 8, 2025).
- What is the market cap and P/E ratio for BALAXI?
- Curious about Balaxi's size and valuation? Its market capitalization stands at 2.43B. When it comes to valuation, the P/E ratio (trailing twelve months) is 10.50, and the forward P/E (looking ahead) is N/A.
- Does BALAXI pay dividends? If so, what's the yield?
- As for dividends, Balaxi isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Balaxi's main competitors or similar companies to consider before investing?
When looking at Balaxi, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON486.32B Healthcare Biotechnology 8.09% 17.05% OneSource Specialty
ONESOURCE214.64B Healthcare Biotechnology 10.61% 10.61% Dishman Carbogen
DCAL37.57B Healthcare Biotechnology 22.14% 106.15% Zota Health Care
ZOTA31.09B Healthcare Biotechnology 85.82% 335.52% Panacea Biotec
PANACEABIO25.12B Healthcare Biotechnology 204.85% 215.33% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Balaxi Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Balaxi's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1.24%, the Debt to Equity ratio from the most recent quarter is 9.64, and its Gross Profit Margin stands at 48.13%.
- What is the recent revenue and earnings growth for BALAXI?
- Looking at Balaxi's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -25.80%, and quarterly earnings saw a YoY growth of 35.00%.
- How much of BALAXI stock is held by insiders and institutions?
- Wondering who owns Balaxi stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.